Share this Article
Copyright: © Singapore Medical Association
Although there is no causal treatment of mitochondrial disorders (MIDs) yet available,(1) treatment strategies to enhance respiratory chain (RC) functions, eliminate noxious compounds, shift the heteroplasmy rate, alter mitochondrial dynamics, transfer cytoplasm, or treat genes are increasingly applied.(1) One of the pharmacological compounds repeatedly reported for treating MIDs are glucocorticoids (GCs).(2) GCs may exhibit either beneficial or detrimental effects, or none at all. However, while the mechanism of action of GCs in the treatment of MIDs remains largely unknown, there are indications that GCs act not only in the nucleus but also in mitochondria.(3,4) Herein, we summarise and discuss the role of GCs in the treatment of human MIDs.
With regard to mode of action, there is increasing evidence that mitochondria are controlled by the action of GCs, as GC receptors are found in mitochondria and GC response elements also reside in mitochondrial DNA (mtDNA).(3) The expression of mtDNA genes can thus be regulated by either interaction with nuclear genes or direct action of GCs on the mtDNA and its RC, transfer RNA, and ribosomal RNA genes.(3) Additionally, GCs directly stimulate mitochondrial transcription via mitochondrial GC receptors, affecting RC biosynthesis.(4) GCs have also been shown to enhance mitochondrial biogenesis and modulate the intrinsic, but not the extrinsic, pathway of apoptosis,(5) and induce apoptosis, upregulate Bim, decrease mitochondrial membrane potential, release cytochrome c and cause DNA fragmentation.(6)
Regarding the clinical effect of GCs on MIDs published in the literature, there are only case reports or case series available (
Effects of glucocorticoids in mitochondrial disorders (MIDs).
In conclusion, the evidence level for a beneficial effect of GCs in MIDs is low. Only case reports are available and no randomised controlled trials have been carried out to investigate the effect of GCs in the treatment of MIDs. Although single cases seem to profit from the use of GCs, others may experience disease deterioration. At present, there is limited evidence to support deciding which cases will benefit from the use of GCs, and in which cases the use of GCs will be detrimental. MELAS patients seem to profit from the use of GCs, whereas KSS patients seem to experience disadvantages.
|1. DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013; 9:429-44.
|2. Walcott BP, Edlow BL, Xia Z, et al. Steroid responsive A3243G mutation MELAS: clinical and radiographic evidence for regional hyperperfusion leading to neuronal loss. Neurologist 2012; 18:159-70.
|3. Lee SR, Kim HK, Song IS, et al. Glucocorticoids and their receptors: insights into specific roles in mitochondria. Prog Biophys Mol Biol 2013; 112:44-54.
|4. Psarra AM, Sekeris CE. Glucocorticoids induce mitochondrial gene transcription in HepG2 cells: role of the mitochondrial glucocorticoid receptor. Biochim Biophys Acta 2011; 1813:1814-21.
|5. Tiao MM, Lin TK, Chen JB, et al. Dexamethasone decreases cholestatic liver injury via inhibition of intrinsic pathway with simultaneous enhancement of mitochondrial biogenesis. Steroids 2011; 76:660-6.
|6. Nuutinen U, Ropponen A, Suoranta S, et al. Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase kinase-3. Leuk Res 2009; 33:1714-7.
|7. Gubbay SS, Hankey GJ, Tan NT, Fry JM. Mitochondrial encephalomyopathy with corticosteroid dependence. Med J Aust 1989; 151:100-3, 106, 108.
|8. Hsu CC, Chuang YH, Tsai JL, et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand 1995; 92:252-5.
|9. Rossi FH, Okun M, Yachnis A, Quisling R, Triggs WJ. Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 2002; 8:313-5.
|10. Bedlack RS, Vu T, Hammans S, et al. MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2004; 29:364-8.
|11. Schiariti M, Cacciola MT, Pangallo A, Ciancia F, Puddu PE. Delayed pericarditis and cardiac tamponade associated with active-fixation lead pacemaker in the presence of mitochondrial myopathy and Ockham's razor. J Cardiovasc Med (Hagerstown) 2009; 10:879-82.
|12. Heiman-Patterson TD, Argov Z, Chavin JM, et al. Biochemical and genetic studies in a family with mitochondrial myopathy. Muscle Nerve 1997; 20:1219‑24.
|13. Mastaglia FL, Thompson PL, Papadimitriou JM. Mitochondrial myopathy with cardiomyopathy, lactic acidosis and response to prednisone and thiamine. Aust N Z J Med 1980; 10:660-4.
|14. Fox C, Dunne J. Corticosteroid responsive mitochondrial encephalomyopathy. Aust N Z J Med 1993; 23:522-3.
|15. Finsterer J, Höger F. Multi-system mitochondrial disorder with recurrent steroid-responsive eosinophilia. Rheumatol Int 2009; 30:135-9.
|16. Shapira Y, Cederbaum SD, Cancilla PA, Nielsen D, Lippe BM. Familial poliodystrophy, mitochondrial myopathy, and lactate acidemia. Neurology 1975; 25:614-21.
|17. Skoglund RR. Reversible alexia, mitochondrial myopathy, and lactic acidemia. Neurology 1979; 29:717-20.
|18. Santos-García D, Abella J, De Domingo B, de la Fuente-Fernández R. Leber hereditary optic neuropathy associated with malabsorption syndrome after bariatric surgery. J Neuroophthalmol 2009; 29:75-6.
|19. Barak Y, Arnon S, Wolach B, et al. MELAS syndrome: peripheral neuropathy and cytochrome C-oxidase deficiency: a case report and review of the literature. Isr J Med Sci 1995; 31:224-9.
|20. Sharfstein SR, Gordon MF, Libman RB, Malkin ES. Adult-onset MELAS presenting as herpes encephalitis. Arch Neurol 1999; 56:241-3.
|21. Feinsmith BM, Liebesman WP, Guibor P. Steroid danger in Kearns-Sayre syndrome (KSS). N J Med 1988; 85:659-63.
|22. Curless RG, Flynn J, Bachynski B, et al. Fatal metabolic acidosis, hyperglycemia, and coma after steroid therapy for Kearns-Sayre syndrome. Neurology 1986; 36:872-3.
|23. Bachynski BN, Flynn JT, Rodrigues MM, et al. Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome. Ophthalmology 1986; 93:391-6.